NIASPAN TABLET (EXTENDED-RELEASE)

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

NICOTINIC ACID

থেকে পাওয়া:

SUNOVION PHARMACEUTICALS CANADA INC

এটিসি কোড:

C10AD02

INN (আন্তর্জাতিক নাম):

NICOTINIC ACID

ডোজ:

750MG

ফার্মাসিউটিকাল ফর্ম:

TABLET (EXTENDED-RELEASE)

রচনা:

NICOTINIC ACID 750MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

30

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

MISCELLANEOUS ANTILIPEMIC AGENTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0108396016; AHFS:

অনুমোদন অবস্থা:

CANCELLED POST MARKET

অনুমোদন তারিখ:

2012-08-02

পণ্য বৈশিষ্ট্য

PRODUCT MONOGRAPH
PR
NIASPAN
®
Extended-Release Niacin
500 mg, 750 mg, 1000 mg Extended-Release Tablets
Lipid Metabolism Regulator
Manufacturer:
DATE OF PREPARATION:
Sunovion Pharmaceuticals Canada Inc.
October 11, 2011
6790 Century Ave. Suite 100
Mississauga, Ontario
Canada
Submission #: 149932
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................ 3
SUMMARY PRODUCT
INFORMATION................................................................................
3
INDICATIONS AND CLINICAL
USE......................................................................................
3
CONTRAINDICATIONS...........................................................................................................
3
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
7
DRUG
INTERACTIONS..........................................................................................................
10
DOSAGE AND
ADMINISTRATION......................................................................................
12
OVERDOSAGE
........................................................................................................................
15
ACTION AND CLINICAL
PHARMACOLOGY....................................................................
15
STORAGE AND STABILITY
.................................................................................................
17
DOSAGE FORMS, COMPOSITION AND
PACKAGING..................................................... 17
PART II: SCIENTIFIC INFORMATION
..............................................................................
19
PHARMACEUTICAL INFORMATION
.................................................................................
19
CLINICAL
TRIALS..............................................................................................